Clinical Utility
The Com.Pl.i.t DX Lung assay provides valuable information that can be utilized for selecting the optimal targeted treatment for patients. By analyzing many genes at the same time it provides a detailed blueprint of the biology of the tumor, which is used by the treating physician to individualize the patient’s treatment plan.
Com.pl.i.t DX Lung is a comprehensive molecular profile for NSCLC patients with prognostic and mainly predictive value, using, according to the guidelines, the correct methodology for the 9 approved targeted therapies:
- EGFR, BRAFV600E, KRASG12C, ERBB2 (DNA sequencing)
- ALK, ROS1, RET, NTRK1,2,3 (RNA sequencing)
- MET exon 14 skipping mutation (DNA & RNA sequencing)